Tweet
FluTrackers Policy A/H1N1 Vaccine Selection for Northern Hemisphere 2010 - 2011
After considering many issues regarding the selection of the strain for the A/H1N1 vaccine for the Northern Hemisphere 2010 - 2011 season, we urge all governmental bodies, both national and international, to select a strain that contains mutations that affect severity and is broad based enough to help most of the world's populations.
As we all know, the virus has changed since creation of the A/H1N1 vaccine now presently in use. We have heard over and over again from many experts in the fields of virology, genetics, biology, medicine, epidemiology, and public health that we are learning more in this pandemic about how viruses behave.
Recent information has concerned us that the current A/H1N1 vaccine strain may not be the best choice for the next Northern Hemisphere season. Faced with a potential/probable loss of oseltamivir as a tool to fight future waves of pandemic virus we believe that a closely matching vaccine is the best public health policy for the world:
Spain: total 80 mutations registered
http://www.flutrackers.com/forum/sho...d.php?t=142368
Mexico - Mutation A/H1N1 virus, resistant to Tamiflu
Observed association between the HA1 mutation D222G in the 2009 pandemic influenza A(H1N1) virus and severe clinical outcome, Norway 2009-2010
"...A large proportion of the fatal and severe cases had underlying risk conditions. However, some of the D222G cases manifested themselves as a rapid unexpected deterioration after a period of mild symptoms in previously healthy subjects, and we consider it likely that there is a causal relationship between the occurrence of the D222G mutation in this virus and severe disease..."
We know that there are many factors in the severity of disease. One is the overall condition of the victim. And we also know that there are probably other proteins/acids and the synergy of these combinants that is at least partially responsible for disease severity.
Simply put, we want the current circulating strains of A/H1N1, that represent the most risk to the world's citizens, to be considered for selection for the pandemic A/H1N1 vaccine for the Northern Hemisphere 2010 -2011.
The Directors of FluTrackers.com Inc.
.
As we all know, the virus has changed since creation of the A/H1N1 vaccine now presently in use. We have heard over and over again from many experts in the fields of virology, genetics, biology, medicine, epidemiology, and public health that we are learning more in this pandemic about how viruses behave.
Recent information has concerned us that the current A/H1N1 vaccine strain may not be the best choice for the next Northern Hemisphere season. Faced with a potential/probable loss of oseltamivir as a tool to fight future waves of pandemic virus we believe that a closely matching vaccine is the best public health policy for the world:
Spain: total 80 mutations registered
http://www.flutrackers.com/forum/sho...d.php?t=142368
Mexico - Mutation A/H1N1 virus, resistant to Tamiflu
Observed association between the HA1 mutation D222G in the 2009 pandemic influenza A(H1N1) virus and severe clinical outcome, Norway 2009-2010
"...A large proportion of the fatal and severe cases had underlying risk conditions. However, some of the D222G cases manifested themselves as a rapid unexpected deterioration after a period of mild symptoms in previously healthy subjects, and we consider it likely that there is a causal relationship between the occurrence of the D222G mutation in this virus and severe disease..."
We know that there are many factors in the severity of disease. One is the overall condition of the victim. And we also know that there are probably other proteins/acids and the synergy of these combinants that is at least partially responsible for disease severity.
Simply put, we want the current circulating strains of A/H1N1, that represent the most risk to the world's citizens, to be considered for selection for the pandemic A/H1N1 vaccine for the Northern Hemisphere 2010 -2011.
The Directors of FluTrackers.com Inc.
.
Comment